Integrative medicine is a hot field right now with more and more patients exploring complimentary and alternative treatments. Why shouldn’t some of these remedies work? After all, plenty of medicines are derived from the nature around us. One such example is lovastatin (also known by the brand name Mevacor), a medication used to lower cholesterol which is derived from red yeast rice, a supplement used in Traditional Chinese Medicine since 800 A.D. that’s produced by cultivating a red-colored mold on rice. A study published in the current issue of Annals of Internal Medicine demonstrates the efficacy of red yeast rice in improving the lipid profiles of people with high cholesterol. When compared with another popular cholesterol-lowering medication, simvastatin (Zocor), red yeast rice was able to lower LDL levels just as effectively. But, similar to prescription lipid-lowering drugs, red yeast rice can have similar side effects on the liver and muscles. So why isn’t your physician recommending red yeast rice? The reasons are plenty, but one main cause is the currently under-regulated U.S. supplements industry where it may be difficult to accurately know how much of a medicinally active ingredient you are receiving, and consistently so. Regardless, red yeast rice may be a viable alternative for cholesterol reduction in certain people who may not be able to tolerate synthetically manufactured medications due to their side effects. [via Annals of Internal Medicine]
Share your comments here.


Dr. Steven Chang, the author of DailyDose, is a staff physician with Kosmix RightHealth. Dr. Chang practices Family Medicine at the University of California Davis Medical Center, where his medical interests include both pediatric and geriatric care, public health, gay and lesbian health, and sleep medicine. Dr. Chang trained at the Stanford University affiliated O'Connor Hospital, and was a research fellow at the National Institute of Health. He holds an M.D. from McGill University and a BA in Public Health from Johns Hopkins University.